Sleep apnea pill maker Apnimed files for US IPO as biotech market revives

• AD109, a once-daily pill taken at bedtime, has a marketing application submitted with an expected FDA decision in Q1 2027
• The IPO comes as biotech sector recovers after IPO activity plunged to decade lows in 2023, with fresh capital returning to the industry
• BofA Securities, Evercore ISI, Cantor, and LifeSci Capital are underwriting the offering for the company founded in 2017

Summary

Apnimed IPO Filing Signals Biotech Sector Recovery

Apnimed, a late-stage clinical pharmaceutical company, filed for a U.S. initial public offering on July 10, marking another sign of revival in the biotech sector after a prolonged downturn. The filing comes as fresh capital returns to the industry, improving market sentiment following biotech IPOs hitting their lowest levels in over a decade in 2025.

Company Overview:

Founded in 2017, Apnimed specializes in developing oral medications for obstructive sleep apnea (OSA) and related disorders. The company's lead drug candidate, AD109, is a once-daily pill taken at bedtime designed to treat OSA.

Key Milestones:

• In May, AD109 successfully met its primary endpoint in a late-stage clinical trial
• The drug offers a potential alternative to traditional device-based treatments for sleep apnea
• Apnimed has already submitted a marketing application to the FDA
• Expected FDA decision date: Q1 2027

Deal Structure:

The underwriting team includes BofA Securities, Evercore ISI, Cantor, and LifeSci Capital. Specific offering size and pricing details were not disclosed in the filing.

Market Implications:

This IPO represents growing investor confidence in the biotech sector's recovery trajectory. The sleep apnea treatment market presents significant commercial opportunity, as AD109 could disrupt the device-dominated OSA treatment landscape with a convenient pharmaceutical option. The successful late-stage trial results and pending FDA review position Apnimed as a potentially attractive investment for healthcare-focused portfolios seeking exposure to innovative therapeutic solutions.